共 42 条
- [21] Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 studyBJU INTERNATIONAL, 2020, 125 (05) : 709 - 717Yoshida, MasakiTakeda, MasayukiGotoh, MomokazuYokoyama, OsamuKakizaki, HidehiroTakahashi, SatoruMasumori, NaoyaNagai, ShinjiMinemura, Kazuyoshi
- [22] Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trialBJU INTERNATIONAL, 2008, 102 (09) : 1120 - 1127Cardozo, LindaHessdoerfer, ElkeMilani, RodolfoArano, PedroDewilde, LucSlack, MarkDrogendijk, TedWright, MarkBolodeoku, John
- [23] Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical TrialFEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2021, 27 (07): : 450 - 456McCammon, KurtGousse, AngeloKohan, AlfredGlazier, DavidGruenenfelder, JenniferBai, ZhanyingPatel, AnandHale, Douglass
- [24] A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladderINTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (09) : 809 - 815Homma, YukioYamaguchi, TakuhiroYamaguchi, Osamu
- [25] Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding StudyLUTS-LOWER URINARY TRACT SYMPTOMS, 2015, 7 (02) : 84 - 92Yamaguchi, OsamuMarui, EijiIgawa, YasuhikoTakeda, MasayukiNishizawa, OsamuIkeda, YasushiOhkawa, Sumito
- [26] EARLY AND CONSISTENT IMPROVEMENTS IN URINARY SYMPTOMS AND QUALITY OF LIFE WITH ONABOTULINUMTOXINA IN OVERACTIVE BLADDER PATIENTS WITH URINARY INCONTINENCE IN A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 4 TRIALTOXICON, 2018, 156 : S79 - S79McCammon, KurtGousse, AngeloGruenenfelder, JenniferHale, DouglassOrejudos, AmeliaAboushwareb, TamerPatel, AnandKohan, Alfred
- [27] International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWURJOURNAL OF UROLOGY, 2020, 204 (02) : 316 - 323Staskin, DavidFrankel, JeffreyVarano, SusannShortino, DeniseJankowich, RachaelMudd, Paul N., Jr.
- [28] Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialJOURNAL OF UROLOGY, 2024, 212 (02) : 267 - 279Takahashi, SatoruKato, KumikoYokoyama, OsamuTakei, MineoGotoh, Momokazu
- [29] Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a 3-adrenoceptor agonist, in patients with overactive bladder in AsiaNEUROUROLOGY AND URODYNAMICS, 2015, 34 (07) : 685 - 692Kuo, Hann-ChorngLee, Kyu-SungNa, YanqunSood, RajeevNakaji, ShigeruKubota, YosukeKuroishi, Kentarou
- [30] Phase III, randomised, double-blind, placebo-controlled study of the 3-adrenoceptor agonist mirabegron, 50mg once daily, in Japanese patients with overactive bladderBJU INTERNATIONAL, 2014, 113 (06) : 951 - 960Yamaguchi, OsamuMarui, EijiKakizaki, HidehiroHomma, YukioIgawa, YasuhikoTakeda, MasayukiNishizawa, OsamuGotoh, MomokazuYoshida, MasakiYokoyama, OsamuSeki, NarihitoIkeda, YasushiOhkawa, Sumito